… Biosimilars promise to expand accessibility to anti-TNF-α … With biologic drug patents expired
or set to expire, biosimilars have … cost driver for the treatment of inflammatory bowel disease. …

… disease, six psoriasis (PSO) and six inflammatory bowel … coding gene sequences have no
elements cloned from any other … among patients in the naïve anti-TNF group compared to the …

… health inequalities in drug availability. In this context, this … uptake of anti-TNF agents in
inflammatory bowel disease (IBD). … no underlying variation in disease characteristics. Although the …

… drug monitoring (TDM)-based dosing with anti-TNF agents in … differences in biochemical
characteristics. The approval of CT-… To date, clinical data with ADL biosimilars are only available …

… of biosimilars, as well as therapeutic drug monitoring for … for the approval of anti-TNF
biosimilars in CD and UC. None … , as well as the test characteristics of existing TDM assays. Long-…

… Biosimilars and Switching BSs of anti-TNF agents are now … Review article: consensus
statements on therapeutic drug … after anti-TNF discontinuation in inflammatory bowel disease: …

… the role of biosimilars in inflammatory bowel disease in terms … in patients has the potential
for large drug-acquisition cost-… and biological characteristics of the infliximab biosimilar SB2, …

… influence the pharmacology of the biosimilar and their … , the biosimilar must demonstrate
several features, including … Our current FDA-approved, anti-TNF biosimilars are not deemed …

… A biosimilar is a biological drug that is very similar to a … demonstrated in terms of quality
characteristics, biological activity, … As new biosimilar anti-TNF products are entering the market, a …

… In this review, real life data available in inflammatory bowel … on anti-TNF therapy failures
in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J …